Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs 10X Genomics Inc (TXG) Price & Performance

iShares 7-10 Year Treasury Bond ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

iShares 7-10 Year Treasury Bond ETF vs 10X Genomics Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.42 (market cap $41.24B), while 10X Genomics Inc trades at $79.01 (market cap $9.92B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 4.2× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and 10X Genomics Inc for 92 Days on average.

IEFTXG
Market Cap
$41.24B$9.92B
Volume
9,141,9679,372,166
Sector
Fixed IncomeHealth
52-Week High
$97.99$97.74
52-Week Low
$88.92$11.48
Typical Hold Time
108 Days92 Days
Enterprise Value
—$9.44B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 7-10 Year Treasury Bond ETF

IEF trades at $89.11, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bearish trend with moving averages overwhelmingly negative, though oscillators suggest potential oversold conditions. Recent dividend distributions of $0.31-$0.33 per share provide income support. The bond ETF faces headwinds from rising Treasury yields and inflation concerns, with market sentiment leaning defensive amid ongoing bond market volatility.

The outlook remains cautious as IEF navigates the highest Treasury yields in decades. While current yields create potential entry points for income-focused investors, persistent inflation and Federal Reserve policy uncertainty pose significant risks. The ETF's defensive positioning may appeal during market turbulence, but further yield increases could pressure prices lower.

10X Genomics Inc

10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.

The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IEF
96% Buy4% Sell
Avg holding period · 108 Days
TXG
4% Buy96% Sell
Avg holding period · 92 Days

Top news

Latest headlines on both assets

About iShares 7-10 Year Treasury Bond ETF

The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.

Read more on IEF →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →